Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


bioMérieux Q3 benefits from H1N1 pandemic

This article was originally published in Clinica

Executive Summary

The H1N1 pandemic over the summer helped to drive sales of bioMérieux's influenza tests and related instruments, enabling the French IVD company to record an 11.2% like-for-like growth in third-quarter sales at €305.9m ($457.3m). Excluding this positive impact, Q3 sales growth increased 7%. The quarter also saw instrument sales in North America return to growth for the first time in nearly two years – bioMérieux’s North American sales have been hit particularly hard by the recession which has led hospitals to curb their spending on expensive capital equipment. Third-quarter sales in this region increased 7.1% to €73m, while European sales grew 8.9% to €167.5m. The Marcy L'Etoile firm continued its expansion in the emerging international markets, where sales increased 29.4% in Latin America (at €24.5m) and 18.8% in Asia-Pacific (at €40.9m). bioMérieux reaffirmed its 2009 sales growth target of 5-7%, and expects operating margin for the year to be over 17%.

You may also be interested in...

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts